Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Sep 2.
doi: 10.1002/ejhf.70022. Online ahead of print.

Low-dose digoxin improves cardiac function in patients with heart failure, preserved ejection fraction and atrial fibrillation - the RATE-AF randomized trial

Karina V Bunting  1   2 , Asgher Champsi  1   3   4 , Simrat K Gill  1   2 , Khalil Saadeh  2 , A John Camm  5 , Mary Stanbury  6 , Sandra Haynes  6 , Jonathon N Townend  1   2 , Richard P Steeds #  1   2 , Dipak Kotecha #  1   3   4 ; on behalf of the RAte control Therapy Evaluation in Permanent Atrial Fibrillation (RATE‐AF) Trial Group
Affiliations

Low-dose digoxin improves cardiac function in patients with heart failure, preserved ejection fraction and atrial fibrillation - the RATE-AF randomized trial

Karina V Bunting et al. Eur J Heart Fail. .

Abstract

Aims: To compare the effect of digoxin versus beta-blockers on left ventricular function, in patients with permanent atrial fibrillation (AF) and symptoms of heart failure within the RATE-AF randomized trial.

Methods and results: Blinded echocardiograms were performed at baseline and 12-month follow-up using a pre-defined imaging protocol and the index-beat approach. The change in systolic and diastolic function was assessed, stratified by left ventricular ejection fraction (LVEF). Overall, 145 patients completed follow-up, with median age 75 years (interquartile range 69-82) and 44% women. In 119 patients with baseline LVEF ≥50%, a significantly greater improvement in systolic function was noted in patients randomized to low-dose digoxin versus beta-blockers: adjusted mean difference for LVEF 2.3% (95% confidence interval [CI] 0.3-4.2; p = 0.021), s' 1.1 cm/s (95% CI 1.0-1.2; p = 0.001) and stroke volume 6.5 ml (95% CI 0.4-12.6; p = 0.037), with no difference in global longitudinal strain (p = 0.11) or any diastolic parameters. There were no significant differences between groups for patients with LVEF 40-49% and <40%. Digoxin reduced N-terminal pro-B-type natriuretic peptide compared to beta-blockers (geometric mean difference 0.77; 95% CI 0.64-0.92; p = 0.004), improved New York Heart Association functional class (odds ratio [OR] 11.3, 95% CI 4.3-29.8; p < 0.001) and modified European Heart Rhythm Association arrhythmia symptom class (OR 4.91, 95% CI 2.36-10.23; p < 0.001), with substantially less adverse events (incident rate ratio 0.21, 95% CI 0.13-0.31; p < 0.001). There were no interactions between treatment effects and baseline LVEF for these outcomes (interaction p = 0.62, 0.49, 0.07 and 0.13, respectively).

Conclusions: Low-dose digoxin in patients with symptoms of heart failure, preserved LVEF and permanent AF leads to a significantly greater improvement in systolic function compared to treatment with beta-blockers.

Keywords: Atrial fibrillation; Beta‐blockers; Digoxin; Echocardiography; Heart failure with preserved ejection fraction; Randomized controlled trial.

PubMed Disclaimer

References

    1. Lane DA, Skjøth F, Lip GYH, Larsen TB, Kotecha D. Temporal trends in incidence, prevalence, and mortality of atrial fibrillation in primary care. J Am Heart Assoc 2017;6:e005155. https://doi.org/10.1161/JAHA.116.005155
    1. Chiang CE, Naditch‐Brûlé L, Murin J, Goethals M, Inoue H, O'Neill J, et al. Distribution and risk profile of paroxysmal, persistent, and permanent atrial fibrillation in routine clinical practice: Insight from the real‐life global survey evaluating patients with atrial fibrillation international registry. Circ Arrhythm Electrophysiol 2012;5:632–639. https://doi.org/10.1161/CIRCEP.112.970749
    1. Ţica O, Khamboo W, Kotecha D. Breaking the cycle of heart failure with preserved ejection fraction and atrial fibrillation. Card Fail Rev 2022;8:e32. https://doi.org/10.15420/cfr.2022.03
    1. Van Gelder IC, Rienstra M, Bunting KV, Casado‐Arroyo R, Caso V, Crijns H, et al. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio‐Thoracic Surgery (EACTS). Eur Heart J 2024;45:3314–3414. https://doi.org/10.1093/eurheartj/ehae176
    1. Kirchhof P, Breithardt G, Bax J, Benninger G, Blomstrom‐Lundqvist C, Boriani G, et al. A roadmap to improve the quality of atrial fibrillation management: Proceedings from the fifth Atrial Fibrillation Network/European Heart Rhythm Association consensus conference. Europace 2016;18:37–50. https://doi.org/10.1093/europace/euv304

LinkOut - more resources